These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38223415)

  • 21. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
    Kobayashi N; Tada T; Nishimura T; Matono T; Yuri Y; Takashima T; Aizawa N; Ikeda N; Fukunishi S; Hashimoto M; Ohyanagi M; Enomoto H; Iijima H
    Hepatol Res; 2024 May; 54(5):429-438. PubMed ID: 38015179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor.
    Platek AE; Szymanska A
    Clin Exp Hepatol; 2023 Sep; 9(3):187-192. PubMed ID: 37790680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial: The Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: Why the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) Consensus Process is Not Representative.
    Fouad YM; Gomaa A; El Etreby RM; AbdAllah M; Attia D
    Med Sci Monit; 2022 Aug; 28():e938066. PubMed ID: 35993179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
    Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
    Moon JH; Jeong S; Jang H; Koo BK; Kim W
    EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.
    Eskridge W; Cryer DR; Schattenberg JM; Gastaldelli A; Malhi H; Allen AM; Noureddin M; Sanyal AJ
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
    Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
    Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
    Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advancements in metabolic-associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions.
    Eeda V; Patil NY; Joshi AD; Awasthi V
    Hepatol Res; 2024 Mar; 54(3):222-234. PubMed ID: 38149861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
    Eslam M; Sanyal AJ; George J;
    Gastroenterology; 2020 May; 158(7):1999-2014.e1. PubMed ID: 32044314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From NAFLD to MASLD: When metabolic comorbidity matters.
    Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
    Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.